We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

38 hedge funds and large institutions have $26.7M invested in Cue Biopharma in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

76% more capital invested

Capital invested by funds: $15.2M → $26.7M (+$11.5M)

6% more funds holding

Funds holding: 36 → 38 (+2)

0.02% more ownership

Funds ownership: 0.53% → 0.56% (+0.02%)

33% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 15

Holders
38
Holders Change
+2
Holders Change %
+5.56%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
10
Reduced
15
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.03M
2
BlackRock
BlackRock
New York
+$274K
3
SPC
Sigma Planning Corp
Michigan
+$267K
4
RJA
Raymond James & Associates
Florida
+$240K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$96.6K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$175K
2
TRCT
Tower Research Capital (TRC)
New York
-$124K
3
DS
DRW Securities
Illinois
-$108K
4
OAM
Oxford Asset Management
United Kingdom
-$91K
5
State Street
State Street
Massachusetts
-$74.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$7.31M +$274K +1,441 +5%
NCM
2
Nantahala Capital Management
Connecticut
$6.79M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.54M +$1.03M +5,441 +55%
State Street
4
State Street
Massachusetts
$2.03M -$74.6K -392 -4%
Northern Trust
5
Northern Trust
Illinois
$1.55M +$69.8K +367 +6%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.13M +$96.6K +508 +12%
Bank of New York Mellon
7
Bank of New York Mellon
New York
$433K +$27K +142 +8%
SFM
8
Sphera Funds Management
Israel
$387K – – –
Charles Schwab
9
Charles Schwab
California
$355K +$80.6K +424 +38%
SPC
10
Sigma Planning Corp
Michigan
$325K +$267K +1,403 New
RJA
11
Raymond James & Associates
Florida
$292K +$240K +1,260 New
Wells Fargo
12
Wells Fargo
California
$266K -$13.1K -69 -6%
TCIM
13
TIAA CREF Investment Management
New York
$236K -$64.1K -337 -25%
UBS Group
14
UBS Group
Switzerland
$235K -$44.3K -233 -19%
California State Teachers Retirement System (CalSTRS)
15
California State Teachers Retirement System (CalSTRS)
California
$218K +$7.04K +37 +4%
TA
16
Teachers Advisors
New York
$192K +$17.1K +90 +12%
State of Wisconsin Investment Board
17
State of Wisconsin Investment Board
Wisconsin
$186K +$35.4K +186 +30%
RhumbLine Advisers
18
RhumbLine Advisers
Massachusetts
$176K – – –
Deutsche Bank
19
Deutsche Bank
Germany
$175K -$1.71K -9 -1%
Morgan Stanley
20
Morgan Stanley
New York
$162K -$175K -918 -57%
Citigroup
21
Citigroup
New York
$130K -$2.47K -13 -2%
WP
22
WealthSource Partners
California
$110K -$36.3K -191 -29%
AIG
23
American International Group
New York
$90K -$380 -2 -0.5%
Millennium Management
24
Millennium Management
New York
$86K +$70.4K +370 New
Bank of America
25
Bank of America
North Carolina
$74K -$33.5K -176 -36%
1
2

CUE Hedge Fund Activity: Q1 2019 in Review

38 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2019, worth a combined $26.7M — up 76% from $15.2M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CUE positions and 2 closed out — a net gain of 2 holders — while 10 added to existing stakes and 15 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.03M. The largest seller was Morgan Stanley, cutting an estimated $175K.

  • 38 institutional investors held Cue Biopharma (CUE) as of Q1 2019, up from 36 in Q4 2018.
  • Funds reported $26.7M of Cue Biopharma stock for Q1 2019, up 76% quarter-over-quarter.
  • 4 funds opened new Cue Biopharma positions in Q1 2019 and 2 closed out, a net change of +2 holders.
  • The largest Cue Biopharma buyer in Q1 2019 was Vanguard Group, an estimated $1.03M added.
  • The largest Cue Biopharma seller in Q1 2019 was Morgan Stanley, an estimated $175K sold.

Based on aggregated 13F filings for Q1 2019.